Log in or Sign up for Free to view tailored content for your specialty!
Hematology News
Enzyme replacement therapy curbs bleeding events in congenital blood clotting disorder
Among patients with congenital thrombotic thrombocytopenic purpura, prophylactic therapy with recombinant ADAMTS13 restored normal levels of the enzyme, according to results of a randomized phase 3 study.
FDA approves one-time gene therapy Beqvez for hemophilia B
The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B.
Many children with sickle cell anemia do not receive recommended preventive care
Many children with sickle cell anemia do not receive guideline-concordant preventive care to reduce their risks for serious infections or stroke, according to research conducted at Children’s Hospital Los Angeles.
Log in or Sign up for Free to view tailored content for your specialty!
Exa-cel a ‘first step’ in gene therapy for sickle cell disease, beta-thalassemia
Exagamglogene autotemcel gave most patients with beta-thalassemia transfusion independence and drastically reduced the number of vaso-occlusive crises in those with sickle cell disease in a pair of phase 3 trials.
Next-generation clot removal system for pulmonary embolism cleared by FDA, launched
Penumbra announced the FDA clearance and launch of its next-generation computer-assisted vacuum thrombectomy system to remove venous thrombus and treat pulmonary emboli.
FDA panel supports imetelstat for anemia in lower-risk myelodysplastic syndrome
An FDA advisory committee voted 12-2 that the benefits of the investigational therapy imetelstat outweigh the risks for the treatment of transfusion-dependent anemia in certain adults with myelodysplastic syndromes.
COVID-19 caused ‘substantial deficit’ of cancer diagnoses in first 10 months of pandemic
More than 130,000 cancer cases went undiagnosed during the first 10 months of the COVID-19 pandemic, researchers estimated in a cross-sectional analysis published in JAMA Oncology.
Expanding clinical trial diversity requires ‘showing up’ in the community to build trust
Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.
ASH president aims to strengthen hematology workforce, address global challenges
Mohandas Narla, DSc, may hold the title of American Society of Hematology president, but his focus for the next several months will extend far beyond this country’s borders.
Language minimizing adverse events in abstracts ‘harmful,’ can affect patient care
Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.
-
Headline News
2024 State of the Air report: 39% of Americans breathe polluted, unhealthy air daily
April 24, 20246 min read -
Headline News
Federal Trade Commission bans most noncompete agreements
April 24, 20243 min read -
Headline News
Genes may play role in heart attack risk during stressful times
April 24, 20242 min read
-
Headline News
2024 State of the Air report: 39% of Americans breathe polluted, unhealthy air daily
April 24, 20246 min read -
Headline News
Federal Trade Commission bans most noncompete agreements
April 24, 20243 min read -
Headline News
Genes may play role in heart attack risk during stressful times
April 24, 20242 min read